ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL) after failure of first-line therapy, followed by brentuximab + bendamustine (Bv + B) for participants with a suboptimal response. CheckMate 744: CHECKpoint pathway and nivolumab clinical
EudraCT number 2016-002347-41
Protocol number CA209-744
Sponsor Bristol-Myers Squibb International Corporation, Chaussée de la Hulpe 185, 1170 Brussels, Belgium
Indications Hemato-oncology
Diagnosis Hodgkin lymphoma
Population in clinical trial Children (2-11 years)
Adolescents (12-17 years)
Adults (18-65 years)
Year of receiving the request to Institute (SÚKL) 2017
Date of approval by Institute (SÚKL) 8.3.2017
Date of approval by EC
Date of initiation CT in ČR
Date of ending CT in ČR 6.1.2020
Sites Fakultní nemocnice v Motole,Klinika dětské hematologie a onkologie,V Úvalu 84,Praha 5,150 06

‹‹ Back to list